Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Assessment of circulating tumor DNA (ctDNA) burden and association with outcomes in metastatic gastric cancer (mGC) patients using real-world data (RWD).
Authors
Senaka A. Peter
Merck & Co., Inc., Rahway, NJ
Senaka A. Peter , Razvan Cristescu , Carol Elaine Pena , Angela Watkins , Carin R. Espenschied , Jiemin Liao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 276)
DOI
10.1200/JCO.2024.42.3_suppl.276
Abstract #
276
Poster Bd #
C14
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO+chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC/GEJC/EAC).
First Author: Ian Chau
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world treatment patterns, testing patterns, and clinical outcomes of first-line (1L) therapy for metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (mGC/GEJC/EAC).
First Author: Sumie Kakehi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world evaluation of clinical outcomes and long-term survivors in patients with BRAF-V600E metastatic colorectal cancer.
First Author: William Phillips
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world performance and clinical outcome of comprehensive genomic profiling of gastrointestinal tumors: High-volume, single-center experience.
First Author: Gianmarco Ricagno